Cardiol Therapeutics Inc.
corporate_fare Company Profile
Cardiol Therapeutics Inc. (NASDAQ:CRDL) is a publicly traded company in the Life Sciences sector. Wiseek monitors CRDL SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Cardiol Therapeutics' Phase II Pericarditis Data Published in JAHA; Phase III Enrollment Nears Completion
- Cardiol Therapeutics Reports Q1 2026 Results, $27.7M Cash, and Extends Runway into Q4 2027
- Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in Journal of American Heart Association
- Cardiol Therapeutics Expands Phase III MAVERIC Trial Network, Reaches 75% Patient Enrollment
- Cardiol Therapeutics Secures Over $30M in Recent Financings, Advances Clinical Pipeline, and Appoints Key Board Member
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for CRDL, detected from its recent SEC filings · based on capital-structure filings through 2026-02-02.
Formalizes Bought Deal Financing · Offering Structure and Pricing
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
CRDL files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.